on Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals and Curie.Bio Sign Research Agreement
Secarna Pharmaceuticals GmbH & Co. KG and a Curie.Bio portfolio company have entered into a research and option agreement. Announced on May 12, 2025, this collaboration aims to develop oligonucleotide therapeutics against an undisclosed target. Secarna will utilize its OligoCreator® platform, designed for rapid and safe therapeutic design.
Under the agreement, Secarna receives a technology access fee, research funding, and warrants for shares upon milestone achievement. This collaboration intends to advance treatment options for conditions currently difficult to treat with conventional methods. It combines Secarna's platform with Curie.Bio's drug discovery expertise.
Secarna's CEO, Konstantin Petropoulos, emphasized the potential to transform scientific innovation into life-changing therapies. This partnership may unlock new avenues for treating complex diseases, leveraging both companies' strengths.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Secarna Pharmaceuticals GmbH & Co. KG news